Phase 3 Recruiting Academic/Other
This phase III trial compares the effect of dose-escalated radiation therapy to usual care in patients with locally advanced unresectable pancreatic ductal adenocarcinoma who have received an initial 4-6 months of chemotherapy. Usual care …
Sponsor: NRG Oncology
NCT ID: NCT06958328
Sites in California: - AIS Cancer Center at San Joaquin Community Hospital — Bakersfield, California
- Alta Bates Summit Medical Center-Herrick Campus — Berkeley, California
- Mills-Peninsula Medical Center — Burlingame, California
- Sutter Cancer Centers Radiation Oncology Services-Cameron Park — Cameron Park, California
- Palo Alto Medical Foundation-Fremont — Fremont, California
Phase 3 Recruiting Network
This phase III trial compares the effect of using lanreotide before surgery to surgery alone in preventing pancreatic fistulas in patients with pancreatic cancer or a pancreatic lesion that could become cancerous. Lanreotide, a type of som…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT06807437
Sites in California: - City of Hope Comprehensive Cancer Center — Duarte, California
- UC San Diego Moores Cancer Center — La Jolla, California
- Veterans Affairs Loma Linda Healthcare System — Loma Linda, California
- USC / Norris Comprehensive Cancer Center — Los Angeles, California
- UC San Diego Medical Center - Hillcrest — San Diego, California
Phase 3 Recruiting Industry
The purpose of this study is to evaluate the efficacy and safety of standard chemotherapy with or without INCB161734 in participants with metastatic pancreatic ductal adenocarcinoma (PDAC).
Sponsor: Incyte Corporation
NCT ID: NCT07522073
Sites in California: - Investigative Site US051 — Duarte, California
- Investigative Site US048 — Fountain Valley, California
- Investigative Site US049 — Irvine, California
- Investigative Site US054 — La Jolla, California
- Investigative Site US027 — Los Angeles, California
Phase 2, Phase 3 Recruiting Industry
The purpose of this study is to assess the safety and efficacy of BMS-986504, a selective, MTA-cooperative PRMT5 inhibitor, in combination with Nab-paclitaxel/Gemcitabine (nab-p/gem) versus placebo in combination with nab-p/gem, in partici…
Sponsor: Bristol-Myers Squibb
NCT ID: NCT07076121
Sites in California: - Scripps Green Hospital — La Jolla, California
- Local Institution - 0157 — San Francisco, California
Phase 2, Phase 3 Recruiting Industry
The primary purpose of this study is to assess the effectiveness of zanzalintinib compared to everolimus in participants with previously treated, unresectable, locally advanced or metastatic neuroendocrine tumors.
Sponsor: Exelixis
NCT ID: NCT06943755
Sites in California: - Exelixis Clinical Site #18 — Beverly Hills, California
- Exelixis Clinical Site #16 — Los Angeles, California
- Exelixis Clinical Site #54 — Palo Alto, California
- Exelixis Clinical Site #12 — Santa Monica, California
- Exelixis Clinical Site #29 — Vallejo, California
Phase 3 Recruiting Industry
The study is a multi-center, open-label, randomized active controlled study of subjects with locally advanced pancreatic adenocarcinoma which is unresectable.
Sponsor: RenovoRx
NCT ID: NCT03257033
Sites in California: - VA Loma Linda Healthcare System — Loma Linda, California
- Sutter Cancer Center Sacramento — Sacramento, California
Phase 3 Recruiting Industry
Pancreatic cancer is difficult to diagnose early. By the time people have been diagnosed, the cancer has usually spread to other parts of the body (metastatic). The standard treatment is chemotherapy, but other treatments are needed to imp…
Sponsor: Astellas Pharma Global Development, Inc.
NCT ID: NCT07409272
Sites in California: - Crosson Cancer Institute at Providence St. Jude Medical Center in Fullerton — Fullerton, California
- Hoag Mem Hosp Presbyterian — Newport Beach, California
Phase 3 Recruiting Industry
The purpose of this study is to evaluate the safety and efficacy of a novel RAS(ON) inhibitor compared to standard of care (SOC) observation only.
Sponsor: Revolution Medicines, Inc.
NCT ID: NCT07252232
Sites in California: - University of California, Los Angeles — Los Angeles, California
- University of California, San Francisco — San Francisco, California
Phase 3 Recruiting Industry
The purpose of this study is to evaluate the safety and efficacy of atebimetinib in combination with modified GnP compared with SOC GnP alone.
Sponsor: Immuneering Corporation
NCT ID: NCT07562152
Sites in California: - City of Hope — Duarte, California
Phase 3 Recruiting Industry
The aim of this Phase 3 study is to evaluate the efficacy of Kinisoquin™ as compared to the placebo in prevention of thromboembolic events in patients with metastatic or locally advanced pancreatic cancer.
Sponsor: Quercis Pharma AG
NCT ID: NCT06861088
Sites in California: - Ventura Clinical Trials — Ventura, California
Phase 2 Recruiting Network
This phase II trial studies the effect of capecitabine and temozolomide after surgery in treating patients with high-risk well-differentiated pancreatic neuroendocrine tumors. Chemotherapy drugs, such as capecitabine and temozolomide, work…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT05040360
Sites in California: - Mission Hope Medical Oncology - Arroyo Grande — Arroyo Grande, California
- PCR Oncology — Arroyo Grande, California
- Tower Cancer Research Foundation — Beverly Hills, California
- Keck Medicine of USC Buena Park — Buena Park, California
- Providence Saint Joseph Medical Center/Disney Family Cancer Center — Burbank, California
Phase 2 Recruiting Academic/Other
This phase II study evaluates how well pemigatinib works for the treatment of adult patients with pancreatic cancer that has spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced) or has s…
Sponsor: Sameek Roychowdhury
NCT ID: NCT06906562
Sites in California: - Ohio State University Telemedicine — Fresno, California
- Ohio State University-Telemedicine — Los Angeles, California
- Ohio State University-Telemedicine — San Diego, California
- Ohio State University-Telemedicine — San Francisco, California
Phase 1, Phase 2 Recruiting NIH
This phase I/II trial studies the safety, side effects and best dose of M3814 and to see how well it works when given together with radiation therapy in treating patients with pancreatic cancer that has spread to nearby tissue or lymph nod…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT04172532
Sites in California: - City of Hope Comprehensive Cancer Center — Duarte, California
- UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care — Irvine, California
- City of Hope at Irvine Lennar — Irvine, California
- UC Irvine Health/Chao Family Comprehensive Cancer Center — Orange, California
- University of California Davis Comprehensive Cancer Center — Sacramento, California
Phase 1, Phase 2 Recruiting Industry
This clinical trial is evaluating a drug called ART0380 in participants with advanced or metastatic solid tumors. The main goals of this study are to: * Find the recommended dose of ART0380 that can be given safely to participants alone an…
Sponsor: Artios Pharma Ltd
NCT ID: NCT04657068
Sites in California: - USC Norris Comprehensive Cancer Center — Los Angeles, California
- Sansum Clinic — Santa Barbara, California
- Providence Medical Foundation — Santa Rosa, California
Phase 2 Recruiting Industry
The purpose of this study is to evaluate the efficacy and safety of adjuvant autogene cevumeran plus atezolizumab and modified leucovorin, 5-fluorouracil (5-FU), irinotecan, and oxaliplatin (mFOLFIRINOX) versus mFOLFIRINOX alone in partici…
Sponsor: Genentech, Inc.
NCT ID: NCT05968326
Sites in California: - USC Norris Comprehensive Cancer Center — Los Angeles, California
- USC Norris Cancer Center — Newport Beach, California
- University of California, San Francisco (UCSF) — San Francisco, California
- University of California Los Angeles — Santa Monica, California
Phase 1, Phase 2 Recruiting Industry
The purpose of this platform study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of novel RAS(ON) inhibitors combined with Standard(s) of Care (SOC) or with novel agents. The current sub…
Sponsor: Revolution Medicines, Inc.
NCT ID: NCT06445062
Sites in California: - UC San Diego Moores Cancer Center — La Jolla, California
- Cedars-Sinai Cancer at Cedars-Sinai Medical Center — Los Angeles, California
- UCLA Hematology/Oncology- Santa Monica — Los Angeles, California
Phase 1, Phase 2 Recruiting Industry
The purpose of this study is to find out whether the study drug, LY3537982, is safe and effective in cancer patients who have a specific genetic mutation (KRAS G12C). Patients must have already received or were not able to tolerate the sta…
Sponsor: Eli Lilly and Company
NCT ID: NCT04956640
Sites in California: - USC Norris Cancer Hospital — Los Angeles, California
- Chao Family Comprehensive Cancer Ctr. — Orange, California
Phase 1, Phase 2 Recruiting Network
This phase I/II trial evaluates the highest safe dose, side effects, and possible benefits of tegavivint in treating patients with solid tumors that has come back (recurrent) or does not respond to treatment (refractory). Tegavivint interf…
Sponsor: Children's Oncology Group
NCT ID: NCT04851119
Sites in California: - Children's Hospital Los Angeles — Los Angeles, California
- Children's Hospital of Orange County — Orange, California
- Lucile Packard Children's Hospital Stanford University — Palo Alto, California
- UCSF Medical Center-Mission Bay — San Francisco, California
Phase 1, Phase 2 Recruiting Industry
Evaluate the safety and tolerability of RMC-6236 in adults with specific RAS mutant advanced solid tumors.
Sponsor: Revolution Medicines, Inc.
NCT ID: NCT05379985
Sites in California: - UC Irvine/Chao Family Comprehensive Cancer Center — Orange, California
- UCLA — Santa Monica, California
Phase 1, Phase 2 Recruiting Industry
This study is to evaluate the safety, tolerability, and PK profiles of Elironrasib and Daraxonrasib as monotherapies and combination therapy in patients with KRAS G12C-mutated solid tumors.
Sponsor: Revolution Medicines, Inc.
NCT ID: NCT06128551
Sites in California: - City of Hope — Duarte, California
- UC IRVINE Health — Orange, California
- UC Davis Comprehensive Cancer Center — Sacramento, California
- Stanford Cancer Institute — Stanford, California
Phase 1, Phase 2 Recruiting Industry
The study treatment, BAY 3713372, is under development to treat MTAP (methylthioadenosine phosphorylase)-deleted solid tumors. It is thought to work by blocking the protein arginine N-methyltransferase 5 (PRMT5). This may kill the MTAP-del…
Sponsor: Bayer
NCT ID: NCT06914128
Sites in California: - City of Hope - Duarte Cancer Center — Duarte, California
- UCLA Health Bowyer Oncology Center — Los Angeles, California
- UCSF Helen Diller Medical Center at Parnassus Heights - Neurology — San Francisco, California
- Stanford University Medical Center - Neurology — Stanford, California
Phase 2 Recruiting Industry
This study is designed to assess the efficacy and safety of ifinatamab deruxtecan (I-DXD) in the following tumor types: endometrial cancer (EC); head and neck squamous cell carcinoma (HNSCC); pancreatic ductal adenocarcinoma (PDAC); colore…
Sponsor: Daiichi Sankyo
NCT ID: NCT06330064
Sites in California: - Los Angeles Cancer Network — Los Angeles, California
- Valkyrie Clinical Trials — Los Angeles, California
- Pih Health Hematology Medical Oncology — Whittier, California
Phase 1, Phase 2 Recruiting Industry
This is a multicenter, open-label, Phase 1/2 study of orally administered VMD-928 monotherapy and in combination with pembrolizumab in adult subjects with advanced solid tumors or lymphoma that have progressed or are non responsive to avai…
Sponsor: VM Oncology, LLC
NCT ID: NCT03556228
Sites in California: - Providence Medical Foundation (site 209) — Santa Rosa, California
Phase 2 Recruiting Industry
This is a study to evaluate the efficacy and safety of belzutifan monotherapy in participants with advanced pheochromocytoma/paraganglioma (PPGL), pancreatic neuroendocrine tumor (pNET), von Hippel-Lindau (VHL) disease-associated tumors, a…
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT04924075
Sites in California: - Cedars-Sinai Medical Center ( Site 0110) — Los Angeles, California
Phase 1, Phase 2 Recruiting Industry
Researchers want to learn if sacituzumab tirumotecan (MK-2870) alone or with other treatments can treat certain gastrointestinal (GI) cancers. The GI cancers being studied are either advanced (the cancer has spread to other parts of the bo…
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06428409
Sites in California: - UCLA ( Site 0317) — Los Angeles, California